Cargando…
Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
A 69‐year‐old man started taking the dipeptidyl peptidase‐4 inhibitor, vildagliptin. One week later, C‐reactive protein and plasma immunoglobulin E levels were markedly elevated, and the vildagliptin was stopped. After the patient's laboratory findings were normalized, we decided to restart vil...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319481/ https://www.ncbi.nlm.nih.gov/pubmed/29607626 http://dx.doi.org/10.1111/jdi.12847 |
_version_ | 1783385067881496576 |
---|---|
author | Anno, Takatoshi Kaneto, Hideaki Kawasaki, Fumiko Shigemoto, Ryo Aoyama, Yumi Kaku, Kohei Okimoto, Niro |
author_facet | Anno, Takatoshi Kaneto, Hideaki Kawasaki, Fumiko Shigemoto, Ryo Aoyama, Yumi Kaku, Kohei Okimoto, Niro |
author_sort | Anno, Takatoshi |
collection | PubMed |
description | A 69‐year‐old man started taking the dipeptidyl peptidase‐4 inhibitor, vildagliptin. One week later, C‐reactive protein and plasma immunoglobulin E levels were markedly elevated, and the vildagliptin was stopped. After the patient's laboratory findings were normalized, we decided to restart vildagliptin with the patient's agreement. The next day, he had a high fever, and C‐reactive protein and procalcitonin levels were elevated. Although we failed to find a focus of infection, we started antibiotics therapy. Two days later, the high fever had improved, and the C‐reactive protein level had decreased. A drug lymphocyte stimulation test showed a positive result for vildagliptin. We examined various kinds of cytokine and infection markers just before and after the treatment with vildagliptin. Finally, we diagnosed the patient with vildagliptin‐induced drug fever, probably based on the increase of various inflammatory cytokine levels and the response to this. Taken together, we should be aware of the possibility of vildagliptin inducing drug fever and/or acute inflammation. |
format | Online Article Text |
id | pubmed-6319481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63194812019-01-08 Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin Anno, Takatoshi Kaneto, Hideaki Kawasaki, Fumiko Shigemoto, Ryo Aoyama, Yumi Kaku, Kohei Okimoto, Niro J Diabetes Investig Articles A 69‐year‐old man started taking the dipeptidyl peptidase‐4 inhibitor, vildagliptin. One week later, C‐reactive protein and plasma immunoglobulin E levels were markedly elevated, and the vildagliptin was stopped. After the patient's laboratory findings were normalized, we decided to restart vildagliptin with the patient's agreement. The next day, he had a high fever, and C‐reactive protein and procalcitonin levels were elevated. Although we failed to find a focus of infection, we started antibiotics therapy. Two days later, the high fever had improved, and the C‐reactive protein level had decreased. A drug lymphocyte stimulation test showed a positive result for vildagliptin. We examined various kinds of cytokine and infection markers just before and after the treatment with vildagliptin. Finally, we diagnosed the patient with vildagliptin‐induced drug fever, probably based on the increase of various inflammatory cytokine levels and the response to this. Taken together, we should be aware of the possibility of vildagliptin inducing drug fever and/or acute inflammation. John Wiley and Sons Inc. 2018-05-02 2019-01 /pmc/articles/PMC6319481/ /pubmed/29607626 http://dx.doi.org/10.1111/jdi.12847 Text en © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Articles Anno, Takatoshi Kaneto, Hideaki Kawasaki, Fumiko Shigemoto, Ryo Aoyama, Yumi Kaku, Kohei Okimoto, Niro Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin |
title | Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin |
title_full | Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin |
title_fullStr | Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin |
title_full_unstemmed | Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin |
title_short | Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin |
title_sort | drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319481/ https://www.ncbi.nlm.nih.gov/pubmed/29607626 http://dx.doi.org/10.1111/jdi.12847 |
work_keys_str_mv | AT annotakatoshi drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin AT kanetohideaki drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin AT kawasakifumiko drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin AT shigemotoryo drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin AT aoyamayumi drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin AT kakukohei drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin AT okimotoniro drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin |